ºÃ§tÅÖºû²§ª«¡@®ð³ÝÃĵΪͼ֪`®g¾¯¹w¨¾©Ê¦^¦¬

2021-07-19 2536

½ÃºÖ³¡­¹Ãĸp¤½§i¡AÄY­«®ð³Ý¥ÎÃĵΪͼ֪`®g¾¯¡A¦]°ê¥~·å²««~¤º§tÅÖºû²§ª«¡A»P°ê¤º¶i¤fªº²£«~¨Ï¥Î¦P§å¥b¦¨«~»s³y¡C³o´Úª`®g¾¯¶È°â¥X1¤ä¡A±N©ó8¤ë8¤é«e¹w¨¾©Ê¦^¦¬¡C

½ÃºÖ³¡­¹Ãĸp¤½§i¡AÄY­«®ð³Ý¥ÎÃÄ¡uµÎªÍ¼Öª`®g¾¯¡v¡A¦]°ê¥~·å²««~¤º§tÅÖºû²§ª«¡A»P°ê¤º¶i¤fªº²£«~¨Ï¥Î¦P§å¥b¦¨«~»s³y¡C³o´Úª`®g¾¯¶È°â¥X1¤ä¡A±N©ó8¤ë8¤é«e¹w¨¾©Ê¦^¦¬¡C

²£«~¦^¦¬

¾Ú½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸pºô¯¸®ø®§¡AµÎªÍ¼Öª`®g¾¯100²@§J/²@¤É Nucala Solution for Injection 100mg/mL

²£«~¡GµÎªÍ¼Öª`®g¾¯100²@§J/²@¤É Nucala Solution for Injection 100mg/mL
³\¥iÃÒ¦r¸¹¡G½Ã³¡µß¬Ì¿é¦r²Ä001144¸¹
§å¸¹¡GFA9M
³\¥iÃÒ«ù¦³ªÌ¡G²ü°Ó¸¯Äõ¯À¥v§JÃļtªÑ¥÷¦³­­¤½¥q¥xÆW¤À¤½¥q
­ì¦]¡G°ê¥~µo²{¦®´¦ÃÄ«~¦³ÅÖºû§¨¦bª`®g¾¹¾À¤W¤§±¡§Î¡A¦]¦®´¦§å¸¹ÃÄ«~«Y¥Ñ¸Ó·å²««~¬Û¦P¤§¥b¦¨«~§å¦¸»s±o¡A°ò©ó¯f¤H¥ÎÃĦw¥þ¡A¬G±Ò°Ê¹w¨¾©Ê¦^¦¬¡C
³Æµù¡G
¤@¡B ­¹Ãĸp¤w­n¨D¼t°ÓÀ³©ó110¦~8¤ë8¤é«e§¹¦¨¦^¦¬§@·~¡A¨ÃÀ³Ãº¥æ¦^¦¬¦¨ªG³ø§i®Ñ¤Î«áÄò¹w¨¾ÁB¥¿±¹¬I¡C
¤G¡B ¸ÓÃÄ«~¥D¦¨¤À¬°Mepolizumab¡A¥D­n¥Î©óÄY­«®ð³Ý¤§ºû«ùªvÀø¡Gªí²{«¬¬°¶Ý¥ì¬õ©Ê¥Õ¦å²yªºÄY­«®ð³Ý¥B±±¨î¤£¨}(severe refractory eosinophilic asthma)¤§12·³¥H¤W¯f¤H¤§ªþ¥[ºû«ùªvÀø¡C ¶Ý¥ì¬õ©Ê¦×ªÞ¸~¨Ö¦hµo©Ê¦åºÞª¢¡GªvÀø¶Ý¥ì¬õ©Ê¦×ªÞ¸~¨Ö¦hµo©Ê¦åºÞª¢[eosinophilic granulomatosis with polyangiitis (EGPA)]¤§¦¨¤H¯f¤H¡A¤Á¤Å¦Û¦æ¥ô·N°±ÃÄ¡C­Õ¹ï¥ÎÃĦ³ºÃ¼{ªÌ¡AÀ³¾¨³t¦^¶E»PÂå®v°Q½×¡A³B¤è¨ä¥L¾A·íÃÄ«~¡C
¤T¡B ½Ð¦UÂåÀø°|©Ò¡BÃÄ°Ó¡BÃħ½°t¦X¿ì²z¦^¦¬§@·~¡A¥ß§Y°±¤î½Õ¾¯¡B¨ÑÀ³¡C

¡i¹Ï¤ù¨Ó·½¡G¤¤¥¡ªÀ¡]½ÃºÖ³¡­¹Ãĸp´£¨Ñ¡^¡j

ment,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', 'UA-35937129-1', 'auto'); ga('send', 'pageview');